Authored by Karl Simpson
At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Flemming Ornskov performed for Shire in 2013.
2013 Liftstream Analysis: Dr. Ornskov steps into Angus Russell’s shoes at the helm of Shire this spring. On his agenda sits a very clear focus towards Shire’s Speciality pharma business and the launch of Vyvanse. In the rare disease space, Shire has portfolio opportunities but probably also needs to get busy with the cheque book and start adding to its portfolio, although it has made some interesting investments in this area, such as Ultragenyx and Bluebird Bio and as we go to press news breaks they acquire Lotus. The question most will be asking is whether Dr. Ornskov can fend off acquisitive interest and make some deals for continued independence and also whether a distinct three franchise operating model works for a company of Shire’s size.
• Define the long-term strategy for Shire
• Execute acquisitions to help bolster Shire’s pipeline
• Look at global organisational structure
2014 Liftstream Verdict: Dr. Ornskov has taken the reigns adeptly, been quick to articulate his vision for ‘one Shire’ that will be built around key areas like rare disease and ophthalmology. The one-shire strategy has seen the organisation undergo a considerable restructure with new managerial appointments, as well as office relocations. He has completed promising strategic acquisitions and added Viropharma for $4.5bn. Overall, Dr. Ornskov has had a stellar start and met the objective we outlined a year ago, all of which is reflected in the share price.
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email firstname.lastname@example.org or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.